Drugs / 8MW2311
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05416749 | Aug 2022 → Mar 2026 | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 8MW2311 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05416749 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of 8MW2311” NCT05416749 ↗ |